TCA’S |
MAOI’S |
SSRI’S |
SNRI’S |
NARI’S |
Tetracyclic and Unicyclic |
5-HT antagonist |
Tertiary amine:
Secondary amine
|
Phenelzine Isocarboxazid Tranylcypromine Selegiline Moclobemide
|
Fluoxetine Sertraline Citalopram Paroxetine Escitalopram
|
Venlafaxine Duloxetine Desvenlafaxine
|
Reboxetine
|
Bupropion Mirtazapine Amoxapine Maprotiline
|
Trazodone Nefazodone Vortioxetine
|
They al promote monoamine activity by increasing NA and 5-HT levels at the central synapse( re-uptake inhibition, degradation inhibition or the blockage of the presynaptic α2 receptor)
The onset of the drug is very slow and can take up to 6-8 weeks for effects to be seen even thou the increase in monoamine concentrations can bw seen within hours after administration due to the action that of the anti-depressants that still needs to be altered in the brain.
TAD’s: needs to be titrated to the minimum effective dose
SSRI’s: can be started on the full dose
TAD’s: sedation, tremors, insomnia, disturbed vision, dry mouth, urinary retention, confusion, orthostatic hypotension, dysrhythmias convulsions, weight gain and sexual dysfunction.
SSRI’s: Insomnia, tremors, GIT disturbances, headache, ↓ libido, sexual dysfunction, anxiety (acute), EPS, withdrawal syndrome. ↓ appetite, non-sedating, acute increase in 5-HT synaptic activity initially causes acute anxiety, later 5-HT decreases again.
TAD’s: Not safe in overdose but it is commonly the drug used for suicide.
SSRI’s: safer with regards to overdose.
Blockade of α2, 5-HT2A, 5-HT2c and 5-HT3 receptors. It also blocks H1 and α1 and causes the indirect stimulation of 5-HT1A
Blockade of 5-HTand NA re-uptake(more potent for 5- HT than for NA).
Moderately selective blockade of SERT and NET
Antagonist: 5-HT2C
Agonist: Melatonergic R’s – MT1 & MT2 &NA release.